Autism has been commonly linked to abnormalities in the immune system. These correlations have contributed immensely to autism research, opening up new possibilities for treatment. One such method currently being explored is the use of mesenchymal stem cells in patients with autism and autism spectrum disorders, and the potential it could have for future treatment.
Dr. Benjamin Gesundheit spoke on his research on mesenchymal stem cells and autism in Israel at the ICare4Autism International Autism Conference this week in Jerusalem. His topic, entitled “Mesenchymal Stromal Stem Cells for Autism Spectrum Disorder- The Therapeutic Rationale and its Future Potential,” highlights this new innovation in autism therapy research, and provided insight for industry professionals.
Dr. Gesundheit discussed how autoimmune mechanisms with chronic neuroinflammation have been connected to the causes of autism spectrum disorder, offering mesenchymal stem cells as a way to open up new therapies for children with autism. He aims to introduce these stem cells more into future clinical studies, claiming that the regenerative, immunomodulary, and anti-inflammatory qualities of the cells will provide innovative alternatives for treatment. While research in this is still preliminary, its continuance is important, and could potentially lead to an immense breakthrough for people with autism everywhere.
Benjamin Gesundheit M.D. Ph.D., currently focuses his research interests on the use of these mesenchymal stem cells in people with ASD. He is a pediatric hematologist oncologist who has had affiliations with the Hospital for Sick Children at the University of Toronto, Hadassah Medical Center, and Hebrew University in Jerusalem. He has had a sufficient amount of experience in experimental cell therapy and bone marrow transplantation, which is applied to his research efforts as well.